Maximus (NYSE:MMS) Issues FY 2026 Earnings Guidance

Maximus (NYSE:MMS) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 7.950-8.250 for the period, compared to the consensus earnings per share estimate of 7.400. The company issued revenue guidance of $5.2 billion-$5.4 billion, compared to the consensus revenue estimate of $5.6 billion.

Maximus Price Performance

MMS stock opened at $77.89 on Thursday. Maximus has a one year low of $63.77 and a one year high of $92.50. The firm has a 50-day moving average of $86.11 and a two-hundred day moving average of $79.33. The firm has a market capitalization of $4.39 billion, a PE ratio of 14.35 and a beta of 0.57. The company has a current ratio of 2.27, a quick ratio of 2.27 and a debt-to-equity ratio of 0.91.

Maximus (NYSE:MMS) last released its quarterly earnings results on Thursday, November 20th. The health services provider reported $1.62 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.01). The firm had revenue of $1.32 billion for the quarter, compared to analyst estimates of $1.34 billion. Maximus had a net margin of 5.83% and a return on equity of 24.44%. The firm’s revenue was up .2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.46 EPS. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. On average, analysts forecast that Maximus will post 6.15 earnings per share for the current year.

Maximus Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be given a $0.30 dividend. This represents a $1.20 annualized dividend and a dividend yield of 1.5%. The ex-dividend date of this dividend is Friday, November 14th. Maximus’s dividend payout ratio (DPR) is 22.10%.

Analysts Set New Price Targets

Several research firms recently weighed in on MMS. Weiss Ratings raised Maximus from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Zacks Research cut Maximus from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $90.00.

Insider Buying and Selling at Maximus

In other news, insider Michelle F. Link sold 1,610 shares of the company’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $90.86, for a total transaction of $146,284.60. Following the completion of the sale, the insider owned 13,508 shares in the company, valued at approximately $1,227,336.88. This represents a 10.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Maximus

Several institutional investors and hedge funds have recently added to or reduced their stakes in MMS. Royal Bank of Canada raised its position in shares of Maximus by 146.2% in the first quarter. Royal Bank of Canada now owns 19,732 shares of the health services provider’s stock valued at $1,345,000 after purchasing an additional 11,716 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Maximus by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock worth $2,351,000 after acquiring an additional 221 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Maximus by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 180,690 shares of the health services provider’s stock worth $12,321,000 after acquiring an additional 11,754 shares during the period. Jane Street Group LLC lifted its position in Maximus by 941.2% during the 1st quarter. Jane Street Group LLC now owns 98,273 shares of the health services provider’s stock worth $6,701,000 after acquiring an additional 88,835 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new stake in Maximus during the second quarter valued at about $204,000. 97.21% of the stock is currently owned by institutional investors and hedge funds.

About Maximus

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.